China Biologic Products Inc (CBPO) : Segantii Capital Management Ltd added new position in China Biologic Products Inc during the most recent quarter end. The investment management firm now holds 50,000 shares of China Biologic Products Inc which is valued at $6,282,000 , the company said in a statement filed on Aug 15, 2016 with the SEC.China Biologic Products Inc makes up approximately 7.87% of Segantii Capital Management Ltd’s portfolio.
Other Hedge Funds, Including , Rudman Errol M reduced its stake in CBPO by selling 27,000 shares or 42.19% in the most recent quarter. The Hedge Fund company now holds 37,001 shares of CBPO which is valued at $4,648,806. China Biologic Products Inc makes up approx 4.28% of Rudman Errol M’s portfolio.Proshare Advisors boosted its stake in CBPO in the latest quarter, The investment management firm added 109 additional shares and now holds a total of 19,793 shares of China Biologic Products Inc which is valued at $2,486,793. China Biologic Products Inc makes up approx 0.03% of Proshare Advisors’s portfolio.Harvard Management Co Inc reduced its stake in CBPO by selling 10,000 shares or 19.88% in the most recent quarter. The Hedge Fund company now holds 40,300 shares of CBPO which is valued at $5,063,292. China Biologic Products Inc makes up approx 1.05% of Harvard Management Co Inc’s portfolio. Blackrock Institutional Trust Company N.a. added CBPO to its portfolio by purchasing 99,786 company shares during the most recent quarter which is valued at $12,537,113. Capital Fund Management S.a. added CBPO to its portfolio by purchasing 2,522 company shares during the most recent quarter which is valued at $296,839. China Biologic Products Inc makes up approx 0.01% of Capital Fund Management S.a.’s portfolio.
China Biologic Products Inc opened for trading at $110 and hit $111.9 on the upside on Thursday, eventually ending the session at $110.57, with a gain of 0.48% or 0.53 points. The heightened volatility saw the trading volume jump to 3,48,703 shares. Company has a market cap of $2,974 M.
On the company’s financial health, China Biologic Products Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.18. The company had revenue of $91.42 million for the quarter, compared to analysts expectations of $87.58 million. The company’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS.
China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).